Latest Content

Share insights on substance use care—practice tips, research, and cases—for Psychiatric Times’ July 2026 series. Pitch your article today.

ASCP panel offers deprescribing guidance to curb psychiatric overprescribing, simplify polypharmacy, and improve outcomes with tapering and

Psychiatrists debunk 10 common antidepressant myths—placebo claims, addiction fears, suicide risk, overuse, and withdrawal—offering evidence-based guidance.

In the first ever episode of "On Your Mind With Erin Crown," explore how tribalism hurts the field of psychiatry and ultimately patient outcomes.

Phase 3b trial shows centanafadine eases adult ADHD and anxiety symptoms fast, with expected safety profile, as FDA review nears.

AI may assist psychopharmacology by aiding suicide risk, digital phenotyping, and TRD care—while exposing EHR data limits and the need for smarter integration.

Track latest neuropsychiatry breakthroughs: phase 3 narcolepsy study launches, new depression and PTSD therapies advance, and FDA approvals reshape care.

Check out the pipeline updates from June!

Largest real-world analysis shows Deep TMS cuts PTSD and depression symptoms in comorbid patients; promising but not FDA-cleared yet.

Transgender psychiatrists of color share APA first-panel insights on identity, allyship, and gender-affirming care—urging intersectional, culturally engaged mental health practice.

Estrogen shapes schizophrenia in women: onset peaks, dosing shifts, and relapse risk from periods to pregnancy, postpartum, and menopause.

Adults born with congenital heart disease face hidden anxiety, PTSD, and cognitive hurdles. See why embedding psychiatry in cardiac care changes outcomes.

Learn how CYP450 genetics, phase 2 metabolism, and drug interactions shape psychiatric dosing—what’s actionable now and what’s next in PPGx.